Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 72 points (-0.5%) at 15,564 as of Friday, Sept. 20, 2013, 12:54 PM ET. The NYSE advances/declines ratio sits at 854 issues advancing vs. 2,087 declining with 92 unchanged. The Health Services industry currently sits up 0.4% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the industry include Insulet Corporation ( PODD), down 5.3%, Catamaran ( CTRX), down 3.5%, Brookdale Senior Living ( BKD), down 2.2% and HCA Holdings ( HCA), down 1.1%. Top gainers within the industry include Agilent Technologies ( A), up 1.8%, Grifols ( GRFS), up 1.3%, Cigna ( CI), up 1.2% and UnitedHealth Group ( UNH), up 0.7%. TheStreet would like to highlight 5 stocks pushing the industry lower today: 5. ResMed ( RMD) is one of the companies pushing the Health Services industry lower today. As of noon trading, ResMed is down $0.63 (-1.2%) to $53.16 on average volume. Thus far, 585,150 shares of ResMed exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $52.88-$53.74 after having opened the day at $53.51 as compared to the previous trading day's close of $53.79. ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. ResMed has a market cap of $7.6 billion and is part of the health care sector. Shares are up 30.8% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate ResMed a buy, no analysts rate it a sell, and 4 rate it a hold. TheStreet Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full ResMed Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.